Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce body weight, glycaemia, blood pressure, postprandial lipaemia and infammation actions that could contribute to the reduction of cardiovascular events
This is more common in semaglutide users and is reported in less than 5% of Ozempic users and 11% of Wegovy users
The dose can be advanced faster at the discretion of your doctor if you are not seeing results and you arent getting side effects
Those with pre-existing diabetic retinopathy should continue with the NHS Diabetic Eye Screening Programme and may require more frequent ophthalmological review, as rapid improvements in glycaemic control can occasionally worsen retinopathy temporarily
Final Thoughts Before-and-after stories about semaglutide can be motivatingbut results often take time
Visible changessuch as cloudiness, discoloration, or particles in the solutionindicate degradation and mean the medication is unsafe to inject